Search Results for: Clinical Roundup
-
As Markets Fancy Biotech, PTC Therapeutics Joins IPO Queue
In 2007, the company inked a blockbuster deal with Pfizer Inc., of New York, focused on its Gene Expression Modulation by Small-molecules (GEMS) technology platform, which identifies small molecules that regulate post-transcriptional control mechanisms...On Friday, the Vetex's shares (NASDAQ:VRTX) gained $1.60, closing at $79.49. -
Clinic Roundup
Celsus Therapeutics plc, of New York, reported interim results from the first cohort of its Phase II trial of MRX-6, a non-steroidal, anti-inflammatory cream, for allergic contact dermatitis...These data led to Eleven's Phase Ib clinical study of EBI-005 in subjects with dry eye disease, with top-line data from the Phase Ib study expected in the second half of 2013 -
Lumena Large: $23M Series A Funds Phase II Cholestatic Bid
Lumena licensed LUM001 from Pfizer Inc., of New York, where the compound was studied as a potential cholesterol-lowering agent...The drug has gone through 12 clinical trials in more than 1,400 subjects already, showing that it knocks down serum bile acid levels safely...Lumena plans to complete the Phase I clinical program of LUM002 in healthy volunteers later this year -
Pharma: Clinic Roundup
Bristol-Myers Squibb Co., of New York, and Pfizer Inc., also of New York, said results from a prespecified subanalysis of the ARISTOTLE trial were published in Circulation, showing that the reductions in stroke or systemic embolism, number of major bleeding events and mortality demonstrated with Eliqus (apixaban) compared to warfarin were consistent across subgroups defined based on levels of International Normalized Ratio control in patients with nonvalvular atrial fibrillation -
Clinic Roundup
Bristol-Myers Squibb Co. (BMS), of New York, disclosed results from a 12-month subgroup analysis of a National Institutes of Health, open-label, long-term research study of metreleptin, an investigational agent for the treatment of metabolic disorders associated with inherited or acquired lipodystrophy (LD...The NH004-3 clinical trial is a double-blind, placebo-controlled, randomized, crossover, multicenter study comparing NH004 and placebo thin films in Parkinson's disease patient complaining of -
Celator Pharmaceuticals Raises $32.5M for Phase III AML Trial
NeoStem Inc., of New York, reported the partial exercise of the overallotment option granted to the underwriters to purchase an additional 1.5 million shares of its common stock, at 50 cents per share, in connection with its recent underwritten public offering of 20 million shares of common stock...The exercise of the overallotment option brings the total gross proceeds from the offering to $10.75 million. (See BioWorld Today, May 1, 2013.) -
Phase III-Ready Anticoagulant Awaits Cash from Regado IPO
NeoStem Inc., of New York, priced an underwritten public offering of 20 million shares of common stock at 50 cents apiece, seeking to generate $10 million...Scioderm is advancing SD-101, a topical cream with a unique mechanism of action, into clinical development in epidermolysis bullosa (EB), a rare genetic condition that results in extremely fragile skin that blisters and tears easily -
ECCMID Roundup
Pfizer Inc., of New York, presented results from a Phase III study investigating immunogenicity, tolerability and safety of Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) in adults 18 to 49...The results of a separate clinical cardiovascular safety study showed that tedizolid was not associated with heart beat abnormalities at up to six times its effective dose, the maximum dose examined in the study -
Clinic Roundup
clinical trials, for SMD and dry age-related macular degeneration (dry AMD...Kythera Biopharmaceuticals Inc., of New York, reported that MRI measurements of patients treated with ATX-101 demonstrated a statistically significant reduction in submental fat (SMF), commonly known as double chin, during an oral session at the Aesthetic Meeting 2013 in New York -
Clinic Roundup
The data were presented at the HemOnc Today Melanoma and Cutaneous Malignancies meeting in New York...dosage form of either tedizolid or linezolid with the option to switch to the respective oral dosage forms at the discretion of the clinical investigator on or after the second day of treatment -
Clinic Roundup
Ohr Pharmaceutical Inc., of New York, said a Phase II trial to evaluate the effects of OHR/AVR118 in advanced cancer patients with cachexia did not meet the primary endpoint of weight gain, but the 18 patients who completed the treatment protocol achieved stable body weight, body fat and muscle mass with a significant increase in appetite (p = 0.001...CALM is investigating the clinical efficacy and safety of Cavatak in Stage IIIc or IV melanoma -
AAN Roundup
BrainStorm Cell Therapeutics Inc., of New York, reported some of the final results from a clinical study evaluating its NurOwn technology in 12 amyotrophic lateral sclerosis (ALS) patients -
Pharma: Clinic Roundup
Pfizer Inc., of New York, said the REMINDER trial of Inspra (eplerenone) showed statistically significant risk reductions in the primary composite efficacy endpoint, defined as time to first event of cardiovascular mortality, re-hospitalization or extended initial hospital stay due to diagnosis of heart failure (HF), sustained ventricular tachycardia or fibrillation, ejection fraction (EF) BioWorld Today | Tuesday, March 12, 2013
Clinic Roundup
The primary objectives include the evaluation of adverse events and the evaluation of six-month clinical response...Intra-Cellular Therapies Inc., of New York, said it completed a Phase I, single-rising-dose study of phosphodiesterase 1 inhibitor ITI-214
Clinic Roundup
TG Therapeutics Inc., of New York, amended its Phase I/II study of single agent ublituximab to initiate its first expansion cohort following early signs of clinical activity
e-Therapeutics Raises $63M to Fund Solid Tumor Drug
As this money is dispensed through its clinical development programs, the company expects to receive £12 million in government R&D tax credits, bringing the total pot to £60 million...BrainStorm Cell Therapeutics Inc., of New York, said it has signed a $250,000 common stock purchase agreement with an individual private investor
Financings Roundup
The net proceeds will be used for working capital and general corporate purposes, including the continuation of the Abili-T clinical study, Opexa's ongoing Phase IIb trial of Tcelna in secondary progressive multiple sclerosis patients...Ventrus Biosciences Inc., of New York, said the underwriter of its previously announced public offering of common stock exercised in full its overallotment option to purchase an additional 870,000 shares of common stock at the public offering price of $2.50 per
Celldex Seeks $90M, End Zone for Rindopepimut
The company plans to use the funds to advance the clinical development programs for rindopepimut, an immunotherapy targeting epidermal growth factor variant III (EGFRvIII) that is in a registration trial in front-line glioblastoma multiforme (GBM), and CDX-011 (glembatamumab vedotin), a fully human monoclonal antibody-drug conjugate (ADC) targeting glycoprotein NMB (GPNMB) that completed a Phase IIb study in breast cancer...Celldex largely eschewed early stage partnerships after it was spurned by
Clinic Roundup
BrainStorm Cell Therapeutics Inc., of New York, began treating its first patient in a Phase IIa trial of its stem cell therapy in amyotrophic lateral sclerosis...The trial will assess safety and clinical benefit of various dose levels of cells
Financings Roundup
DelMar is working on a cancer drug pipeline, including lead asset VAL-083, which is in clinical trials in refractory glioblastoma multiforme...Stemline Therapeutics Inc., of New York, closed its initial public offering of 3.8 million shares, including the exercise in full of the overallotment option covering 497,647 shares, at a price of $10 per share
Category
Current Filters
- xNew York
Related Keywords
Categories
- x BioWorld Today (637)
- x BioWorld International (3)